Michael Hogan, Ph.D. - Vice-President for PepsiCo Foods North America Procurement - PepsiCo | LinkedIn
mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery
Michael Hogan, PhD
Moderna Drops After Losing Appeal Over Drug-Delivery Patents (2)
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines | ACS Central Science
Frontiers | The Limitless Future of RNA Therapeutics
Vaccines | Free Full-Text | An Update on Self-Amplifying mRNA Vaccine Development
Michael Hogan - Senior Advisor - The Regulatory Assistance Project | LinkedIn
mRNA vaccine - Wikipedia
Short Oligonucleotides Facilitate Co-transcriptional Labeling of RNA at Specific Positions | Journal of the American Chemical Society
Nanotechnology for COVID-19: Therapeutics and Vaccine Research | ACS Nano
Michael Hogan, Ph.D. - Vice-President for PepsiCo Foods North America Procurement - PepsiCo | LinkedIn
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development | ACS Central Science
Polymers Strive for Accuracy: From Sequence-Defined Polymers to mRNA Vaccines against COVID-19 and Polymers in Nucleic Acid Therapeutics | Journal of the American Chemical Society
The 'anti-hype' vaccine | Nature Biotechnology
Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement | ACS Nano
mRNA vaccines for infectious diseases: principles, delivery and clinical translation | Nature Reviews Drug Discovery
mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery
Machine Learning for Designing Next-Generation mRNA Therapeutics | Accounts of Chemical Research
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy
SARS-CoV-2 Vaccine Development: An Overview and Perspectives | ACS Pharmacology & Translational Science
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice - ScienceDirect
mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action | npj Vaccines
Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic - Wang - 2022 - Exploration - Wiley Online Library
Michael Hogan - Co-Founder & Chief Scientific Officer @ PathogenDx - Crunchbase Person Profile
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability - ScienceDirect
Vaccines | Free Full-Text | Nanomaterial Delivery Systems for mRNA Vaccines
